GGrantIndex
← Leaderboards

Robert E Shaddy

University Of Utah

Google Scholar ↗PubMed ↗ORCID ↗
$2,067,737
Attributed
$4,684,047
Total exposure
11
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY2005–17
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$4,684,047 · 11

By mechanism

U10$2,660,500 · 1
T32$1,685,286 · 1
M01$338,261 · 9

Top collaborators

Most similar at University Of Utah

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject”

Research focus

Human SubjectClinical ResearchHuman Therapy EvaluationHomologous TransplantationHeart SurgeryChild (0-11)Congenital Heart DisorderChildInfantMortality Vital StatisticsChildhoodDrug Screening /EvaluationHistocompatibility AntigensHeart FailureHeart TransplantationTransplantation ImmunologyBedsBaseAerobic ExerciseAzathioprineCardiac DeathAerobicAdolescentCarbon Dioxide

Grant awards (29)

Training in Molecular Therapeutics for Pediatric Cardiology$3,181
T32 · FY2017 · HL
Training in Molecular Therapeutics for Pediatric Cardiology$579,453
T32 · FY2016 · HL
Training in Molecular Therapeutics for Pediatric Cardiology$594,687
T32 · FY2015 · HL
Sidenafil Impacts Exercise Performance in Adolescent Survivors of the Fontan$502,500
U10 · FY2015 · HL · contact PI
Training in Molecular Therapeutics for Pediatric Cardiology$507,965
T32 · FY2014 · HL
Sidenafil Impacts Exercise Performance in Adolescent Survivors of the Fontan$502,500
U10 · FY2014 · HL · contact PI
Sidenafil Impacts Exercise Performance in Adolescent Survivors of the Fontan$502,500
U10 · FY2013 · HL · contact PI
Sidenafil Impacts Exercise Performance in Adolescent Survivors of the Fontan$148,000
U10 · FY2013 · HL · contact PI
Sidenafil Impacts Exercise Performance in Adolescent Survivors of the Fontan$502,500
U10 · FY2012 · HL · contact PI
Sidenafil Impacts Exercise Performance in Adolescent Survivors of the Fontan$502,500
U10 · FY2011 · HL · contact PI
GENETIC POLYMORPHISMS IN CHILDREN WITH CONGENITAL HEART DISEASE$606
M01 · FY2008 · RR · contact PI
GENETIC POLYMORPHISMS IN CHILDREN WITH CONGENITAL HEART DISEASE$3,860
M01 · FY2007 · RR · contact PI
GENETIC POLYMORPHISMS IN CHILDREN WITH CONGENITAL HEART DISEASE$6,315
M01 · FY2006 · RR · contact PI
CARVEDILOL IN CHILDREN WITH CONGESTIVE HEART FAILURE$33,516
M01 · FY2005 · RR
GENETIC POLYMORPHISMS IN CHILDREN WITH CONGENITAL HEART DISEASE$7,928
M01 · FY2005 · RR
Carvedilol in children with congestive heart failure$26,472
M01 · FY2004 · RR
Genetic polymorphisms in children with congenital heart disease$3,080
M01 · FY2004 · RR
Children with elevated systemic ventricular filling pressures$1,048
M01 · FY2004 · RR
Human allograft implantation in children$852
M01 · FY2004 · RR
CARDIOPULMONARY BYPASS OR PIECES OF HUMAN NON VALVED ALLOGRAFTS$0
M01 · FY2002 · RR
PROSPECTIVE STUDY TO DETERMINE THE EFFICACY AND SAFETY OF AZATHIOPRINE$0
M01 · FY2002 · RR
CARDIOPULMONARY BYPASS OR PIECES OF HUMAN NON VALVED ALLOGRAFTS$248,088
M01 · FY2001 · RR
PROSPECTIVE STUDY TO DETERMINE THE EFFICACY AND SAFETY OF AZATHIOPRINE$1,624
M01 · FY2001 · RR
CARDIOPULMONARY BYPASS OR PIECES OF HUMAN NON VALVED ALLOGRAFTS$1,624
M01 · FY2001 · RR
CARDIOPULMONARY BYPASS OR PIECES OF HUMAN NON VALVED ALLOGRAFTS$0
M01 · FY2001 · RR
PROSPECTIVE STUDY TO DETERMINE THE EFFICACY AND SAFETY OF AZATHIOPRINE$0
M01 · FY2001 · RR
PROSPECTIVE STUDY TO DETERMINE THE EFFICACY AND SAFETY OF AZATHIOPRINE$0
M01 · FY2001 · RR
CARDIOPULMONARY BYPASS OR PIECES OF HUMAN NON VALVED ALLOGRAFTS$1,624
M01 · FY2000 · RR
PROSPECTIVE STUDY TO DETERMINE THE EFFICACY AND SAFETY OF AZATHIOPRINE$1,624
M01 · FY2000 · RR